Target intelligence / Profile preview

Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) (FcγRIIIa)

Target
FcγRIIIa
Molecular classification
Receptor, Immunoglobulin superfamily, Fc receptor family
01

Overview

Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa), also known as CD16a, is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily. It is primarily expressed on natural killer (NK) cells, macrophages, and monocytes, where it serves as a potent activating receptor for the Fc portion of IgG1 and IgG3 antibodies. The primary biological function of FcγRIIIa is to mediate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, providing a critical link between the adaptive and innate immune systems. In clinical practice, FcγRIIIa is the key mediator of the anti-tumor activity of many therapeutic monoclonal antibodies, such as rituximab and trastuzumab. Genetic variations in the FCGR3A gene, specifically the V158F polymorphism, significantly impact the receptor's binding affinity for IgG and are used as biomarkers to predict clinical response to antibody-based therapies. Beyond oncology, FcγRIIIa is implicated in the pathogenesis of autoimmune diseases and the clearance of viral infections, making it a significant target for drug development aimed at either enhancing or modulating immune effector functions.

Other names
CD16aFCGR3AFc-gamma RIIIaFcRIIIaCD16Fc-gamma RIIILow affinity immunoglobulin gamma Fc region receptor III-A
02

Mechanism of action

Facilitates antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis by bridging IgG-coated target cells with effector cells (e.g., NK cells, macrophages). Therapeutic antibodies or bispecific engagers bind to FcγRIIIa to trigger the release of cytotoxic granules and pro-inflammatory cytokines.

03

Biological functions

Immune responseAntibody-dependent cellular cytotoxicityPhagocytosisCytokine productionSignal transductionCell activation
04

Disease associations

CancerAutoimmune diseaseInfectionInflammationImmune thrombocytopenia (ITP)Systemic lupus erythematosus (SLE)
05

Safety considerations

Cytokine release syndromeInfusion-related reactionsNeutropenia (due to potential cross-reactivity with FcγRIIIb)Therapeutic resistance in F158 allele carriers
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

FCGR3A V158F polymorphismCD16a expression levelsNK cell count

Beyond the preview

Go deeper on Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) (FcγRIIIa).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) (FcγRIIIa).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call